This $232,488 Project Grant award from the National Institutes of Health (CFDA 93.310 Trans-NIH Research Support program) aims to develop new sequestration agents for the treatment of intoxication from a range of drugs of abuse, including opioids, stimulants, and hallucinogens. The project will systematically optimize the structure of macrocyclic arene compounds to maximize their binding affinity toward specific drugs, with the goal of promoting clearance of the drugs from the bloodstream. The research will involve in vitro toxicology and in vivo testing to establish the biocompatibility of the sequestration agents, as well as evaluating their efficacy using animal models. The award was made to the University of Maryland, College Park, which will conduct the research over a 2-year period from June 2024 to May 2026. Upon successful completion, the project aims to nominate at least one sequestration agent candidate for further development toward an Investigational New Drug status with the FDA.
Generated 4/1/25, 5:05 AM